Cytolytic CD8+T cell response to SARS-CoV-2 and non-SARS-CoV-2-related viruses is associated with severe manifestation of COVID-19

被引:0
|
作者
Allers, Kristina [1 ,2 ,3 ,7 ]
Moos, Verena [1 ,2 ,3 ]
Hofmann, Jorg [4 ]
Witkowski, Mario [1 ,2 ,5 ]
Haibel, Hildrun [1 ,2 ,3 ]
Angermair, Stefan [1 ,2 ,6 ]
Schneider, Thomas [1 ,2 ,3 ]
机构
[1] Charite Univ Med Berlin, Campus Benjamin Franklin,Hindenburgdamm 30, D-12203 Berlin, Germany
[2] Free Univ Berlin, Campus Benjamin Franklin,Hindenburgdamm 30, D-12203 Berlin, Germany
[3] Humboldt Univ, Div Gastroenterol Infect Dis & Rheumatol, Campus Benjamin Franklin,Hindenburgdamm 30, D-12203 Berlin, Germany
[4] Lab Berlin Charite Vivantes GmbH, Sylter Str 2, D-13353 Berlin, Germany
[5] Humboldt Univ, Inst Microbiol Infect Dis & Immunol, Lab Innate Immun, Campus Benjamin Franklin,Hindenburgdamm 30, D-12203 Berlin, Germany
[6] Humboldt Univ, Klin Anasthesiol Schwerpunkt Operat Intensivmed, Campus Benjamin Franklin,Hindenburgdamm 30, D-12203 Berlin, Germany
[7] Univ Med Berlin, Div Gastroenterol Infect Dis & Rheumatol, Campus Benjamin Franklin,Hindenburgdamm 30, D-12203 Berlin, Germany
关键词
COVID-19; SARS-CoV-2; CD8+T cell response; CytolyticCD8+T cells; Heterologous T cell activation; Bystander activation; CD8(+) T-CELLS; LATENT ADENOVIRAL INFECTION; EPSTEIN-BARR-VIRUS; HEPATITIS-C-VIRUS; INFLUENZA-VIRUS; ANTIVIRAL IMMUNITY; CROSS-REACTIVITY; AUTOCRINE IL-2; MEMORY; EXPRESSION;
D O I
10.1016/j.clim.2023.109712
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Little is known about the CD8+ T cell functionality in the coronavirus disease 2019 (COVID-19). Therefore, we examined twenty-five hospitalized COVID-19 patients with moderate (MD) or severe disease (SD) as well as seventeen SARS-CoV-2-unexposed persons regarding the cytolytic and cytokine-producing reactivity of their CD8+ T cells. Reactive CD8+ T cells were detectable in 90% of the unexposed persons, confirming high cross-reactive immune memory in the general population. Compared to unexposed persons and MD patients, SD pa-tients had higher numbers of SARS-CoV-2 reactive CD8+ T cells with cytolytic function that can simultaneously produce inflammatory cytokines. In addition, SD patients showed higher CD8+ T cell reactivity against non-SARS-CoV-2-related viruses, which was mainly mediated by cytolytic response. Sequence alignments showed that cross-reactivities with the Spike protein could contribute to the expansion of such cells. Since insufficiently regulated cytolytic CD8+ T cells can damage peripheral and vascular tissue structures, high levels of both SARS-CoV-2-reactive and heterologously activated cytolytic CD8+ T cells could favor severe disease progression.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] SARS-CoV-2 and COVID-19
    Sheng, Wang-Huei
    Ko, Wen-Chien
    Huang, Yhu-Chering
    Hsueh, Po-Ren
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2020, 53 (03) : 363 - 364
  • [2] Research Response to SARS-CoV-2/COVID-19
    Burger, Charles D. y
    Mikhail, Amanda E.
    Orenstein, Robert
    Ebbert, Jon O.
    Vergidis, Paschalis
    Badley, Andrew D.
    MAYO CLINIC PROCEEDINGS, 2020, 95 (09) : S52 - S55
  • [3] Impaired SARS-CoV-2 specific T-cell response in patients with severe COVID-19
    Ruemke, Lidewij W.
    Smit, Wouter L.
    Bossink, Ailko
    Limonard, Gijs J. M.
    Muilwijk, Danya
    Haas, Lenneke E. M.
    Reusken, Chantal
    van der Wal, Sanne
    Thio, Bing J.
    van Os, Yvonne M. G.
    Gremmels, Hendrik
    Beekman, Jeffrey M.
    Nijhuis, Monique
    Wensing, Annemarie M. J.
    Heron, Michiel
    Thijsen, Steven F. T.
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [4] Aging and inflammation limit the induction of SARS-CoV-2-specific CD8+T cell responses in severe COVID-19
    Autaa, Gaelle
    Papagno, Laura
    Nogimori, Takuto
    Boizard-Moracchini, Andrea
    Korenkov, Daniil
    Roy, Maeva
    Suzuki, Koichiro
    Masuta, Yuji
    White, Eoghann
    Llewellyn-Lacey, Sian
    Yoshioka, Yasuo
    Nicoli, Francesco
    Price, David A.
    Dechanet-Merville, Julie
    Yamamoto, Takuya
    Pellegrin, Isabelle
    Appay, Victor
    JCI INSIGHT, 2025, 10 (04)
  • [5] Immune response to SARS-CoV-2 in severe disease and long COVID-19
    Sumi, Tomonari
    Harada, Kouji
    ISCIENCE, 2022, 25 (08)
  • [6] Clinical Manifestation and the Risk of Exposure to SARS-CoV-2 (COVID-19)
    Aleebrahim-Dehkordi, Elahe
    Reyhanian, Ali
    Hasanpour-Dehkordi, Ali
    INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, 2020, 11 (01)
  • [7] A deficient immune response to SARS-CoV-2 in the nasopharynx is associated with severe COVID-19 pneumonia
    Pita-Martinez, Carlos
    Perez-Garcia, Felipe
    Berdices, Ana Virseda
    Martin-Vicente, Maria
    Castilla-Garcia, Lucia
    Fernandez, Irene Hervas
    Ventosa, Victoria Gonzalez
    Munoz-Gomez, Maria Jose
    Cuadros-Gonzalez, Juan
    Bermejo-Martin, Jesus F.
    Resino, Salvador
    Martinez, Isidoro
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023, 134 : 126 - 132
  • [8] SARS-CoV-2 specific CD8+ T cell responses in convalescent COVID-19 individuals
    Kared, Hassen
    Redd, Andrew D.
    Bloch, Evan M.
    Bonny, Tania S.
    Sumatoh, Hermi
    Kairi, Faris
    Carbajo, Daniel
    Abel, Brian
    Newell, Evan W.
    Bettinotti, Maria P.
    Benner, Sarah E.
    Patel, Eshan U.
    Littlefield, Kirsten
    Laeyendecker, Oliver
    Shoham, Shmuel
    Sullivan, David
    Casadevall, Arturo
    Pekosz, Andrew
    Nardin, Alessandra
    Fehlings, Michael
    Tobian, Aaron A. R.
    Quinn, Thomas C.
    JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (05):
  • [9] Repurposing CD8+T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?
    Gujar, Shashi
    Pol, Jonathan G.
    Kim, Youra
    Kroemer, Guido
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [10] Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2
    Ameratunga, Rohan
    Woon, See-Tarn
    Steele, Richard
    Lehnert, Klaus
    Leung, Euphemia
    Brooks, Anna E. S.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2022, 18 (06) : 557 - 565